What Researchers Did
Researchers conducted a systematic review and meta-analysis of ten studies to assess how well hyperbaric oxygen therapy (HBOT) treats osteonecrosis of the femoral head (ONFH).
What They Found
After HBOT, patients showed significant improvements in pain levels (Visual Analog Scale mean difference = -2.94), physical health (SF12 PCS mean difference = 17.28), mental health (SF12 MCS mean difference = 4.26), and hip function (Harris hip score mean difference = 26.91, modified Harris hip score mean difference = 44.31). However, when comparing HBOT to non-HBOT groups, there was no significant difference in physical or mental health scores or in the number of patients who improved.
What This Means for Canadian Patients
This study suggests that hyperbaric oxygen therapy is not currently an effective treatment for early-stage osteonecrosis of the femoral head. Canadian patients with this condition should discuss all available treatment options with their healthcare providers, as HBOT is not supported by this review for early ONFH.
Canadian Relevance
No direct Canadian connection identified. Osteonecrosis of the femoral head is not a Health Canada-recognized indication for hyperbaric oxygen therapy.
Study Limitations
The study concluded that more large-scale randomized controlled trials are needed, indicating the current evidence base is insufficient to recommend HBOT for early-stage femoral head necrosis.